NanoViricides Inc 2026年季度报告

QUARTERLY REPORT UNDER SECTION1320 OR 15(d)OFTHE SECURITIES EXCHANGE ACT OF 1934. NANOVIRICIDES,INC. Indicate by check mark whether the Company (1)has filed all reports required to be filed by Section13 or 15(d)of the ExchangeAct during the preceding 12months (or for such shorter period that the Company was required to file such reports), and (2)has Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to besubmittedpursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such shorter Indicate by check mark whether the Company is a larger accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the Company is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ NanoViricides,Inc.FORM10-Q INDEXPART I FINANCIAL INFORMATION3Item 1. Financial Statements3Condensed Balance Sheets at March 31, 2026 (Unaudited) and June 30, 20253Condensed Statements of Operations for the Three and Nine Months Ended March 31, 2026 and 2025(Unaudited)4Condensed Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended March 31,2026 and 2025 (Unaudited)5Condensed Statements of Cash Flows for the Nine Months Ended March 31, 2026 and 2025 (Unaudited)7Notes to the Condensed Financial Statements (Unaudited)8Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3. Quantitative and Qualitative Disclosures About Market Risk52Item 4. Controls and Procedures52PART II OTHER INFORMATION53Item 1. Legal Proceedings53Item 2. Unregistered Sales of Equity Securities and Use of Proceeds53Item 3. Defaults Upon Senior Securities53Item 4. Mine Safety Disclosures53Item 5. Other Information54Item 6. Exhibits and Reports on Form 8-K55Signatures56Certifications PART I. FINANCIAL INFORMATION NanoViricides,Inc.Condensed Statements of Cash Flows Table of Contents NANOVIRICIDES,INC.March 31, 2026NOTESTO THE CONDENSED FINANCIAL STATEMENTS Note1– Organization and Nature of Business NanoViricides,Inc.(the“Company”)is a clinical stage nano-biopharmaceutical company specializing in thediscovery, development, and commercialization of drugs to combat viral infections using its unique and novelnanomedicines technology platform. The Company’s platform is based on host-mimicry, and thereby has uniquelyenabled development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmetneed in antiviral therapeutics. NanoViricides possesses its own facility that supports research and development and NanoViricides, Inc. is domiciled under the laws of the State of Delaware, with its principal operations located in theState of Connecticut. The Company’s fiscal year begins on July 1st and ends on the next June 30th of the calendar Note2– Liquidity and Going Concern The Company’s condensed financial statements have been prepared assuming that it will continue as a going concern,which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course ofbusiness. As reflected in the condensed financial statements, the Company has an accumulated deficit at March 31,2026 of approximately $154.8 million and a net loss of approximately $6.0 million and net cash used in operatingactivities of approximately $5.6 million for the nine months then ended. In addition, the Company has not generated As of March 31, 2026, the Company had available cash and cash equivalents of approximately $3.2 million. TheCompany’s liabilities at March 31, 2026 were approximately $1.1 million including accounts payable of approximately$135,000 payable to third parties, accounts payable to related parties of approximately $905,000, and accruedexpenses of approximately $26,000. Management believes that the Company’s cash and cash equivalents balance ofapproximately $3.2 million, and the Company’s existing resources, including availability under its $3 million line of During the nine month period ended March 31, 2026, the Company raised capital of approximately $1,909,000, net ofoffering expenses, from ATM sales of the Company’s common stock. Additionally, on November 11, 2025, theCompany raised capital of approximately $5.4 million net of expenses in a Registered Direct Offering of common The ability of the Company to continue as a going concern is dependent upon controlling its overall expenses and The Company believes that it has several important milestones, building on the successful Phase Ia/Ib human cli